A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children

Vaccine. 2002 Jun 21;20(21-22):2790-5. doi: 10.1016/s0264-410x(02)00179-2.

Abstract

The reactogenicity and immunogenicity of combined measles and rubella (MR) booster vaccination, via aerosol and subcutaneous routes, was assessed in 562 healthy children. Rates of rubella seroconversion and geometric mean titers (GMT) were similar for both routes. Rates of measles PN seroconversion, GMT and measles ELISA post-vaccination seropositivity and seroconversion rate were each higher for aerosol vaccine (54%, 3928 IU/l, 99.6 and 98.8%), than for subcutaneous vaccine (7%, 866 IU/l, 92.2 and 82.4%) (P<0.01). Reactogenicity was higher for subcutaneous vaccine (P<0.05). This study demonstrates that aerosol vaccine was more immunogenic for measles antibodies, and equally immunogenic for rubella antibodies. Aerosol vaccine was less reactogenic.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aerosols
  • Antibodies, Viral / blood
  • Antibody Formation
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Immunization, Secondary*
  • Injections, Subcutaneous
  • Measles / immunology*
  • Measles Vaccine / administration & dosage*
  • Measles Vaccine / adverse effects
  • Measles Vaccine / immunology
  • Measles virus / immunology
  • Rubella / immunology
  • Rubella / prevention & control
  • Rubella Vaccine / administration & dosage
  • Rubella Vaccine / adverse effects
  • Rubella Vaccine / immunology*

Substances

  • Aerosols
  • Antibodies, Viral
  • Measles Vaccine
  • Rubella Vaccine